Filing Flows › Adaptive Biotechnologies (ADPT) › Q1 2025
Adaptive Biotechnologies (ADPT) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
Adaptive Biotechnologies (ADPT) reported revenue of $52.4M for the first quarter 2025 (Q1 2025), +25% from a year earlier and +11% from the quarter before. Operating margin was -56.4%, net loss $29.8M (56.9% of revenue).
Adaptive Biotechnologies, Q1 2025: revenue $52.4M (+25% year over year), operating margin -56.4%, net loss $29.8M, operating cash flow −$28.5M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $52.4M | +11% | +25% |
| Operating profit | −$29.6M | — | — |
| Net earnings | −$29.8M | — | — |
| Operating cash flow | −$28.5M | — | — |
What changed
Revenue was $52.4M in Q1 2025, up 25% year over year and up 11% from the previous quarter.
Operating costs exceeded revenue by $29.6M, an operating margin of -56.4%. Total costs fell 9% while revenue rose 25%. The quarter ended with a net loss of $29.8M, narrower than the previous quarter's $33.7M loss.
Operating cash flow was −$28.5M. Non-cash charges added back $4.7M of depreciation and amortization and $12.1M of share-based compensation. Working capital and other items used $15.5M. Capital expenditures of $1.3M exceeded it, leaving free cash flow of −$29.7M.
Questions
What was Adaptive Biotechnologies' revenue in the first quarter 2025?
Adaptive Biotechnologies (ADPT) reported revenue of $52.4M for the first quarter 2025 (Q1 2025), +25% from a year earlier and +11% from the quarter before.
Was Adaptive Biotechnologies profitable in the first quarter 2025?
Operating loss was $29.6M (-56.4% of revenue) and net loss $29.8M.